Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cost of Revenue for 9 consecutive years, with $23.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 66.13% year-over-year to $23.1 million, compared with a TTM value of $58.2 million through Dec 2025, down 9.7%, and an annual FY2025 reading of $58.2 million, down 9.7% over the prior year.
  • Cost of Revenue was $23.1 million for Q4 2025 at Puma Biotechnology, up from $12.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $29.6 million in Q1 2021 and bottomed at $10.3 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $15.2 million, with a median of $12.4 million recorded in 2022.
  • The sharpest move saw Cost of Revenue soared 225.66% in 2021, then tumbled 63.31% in 2022.
  • Year by year, Cost of Revenue stood at $11.9 million in 2021, then surged by 41.54% to $16.8 million in 2022, then skyrocketed by 44.47% to $24.3 million in 2023, then tumbled by 42.77% to $13.9 million in 2024, then surged by 66.13% to $23.1 million in 2025.
  • Business Quant data shows Cost of Revenue for PBYI at $23.1 million in Q4 2025, $12.2 million in Q3 2025, and $12.3 million in Q2 2025.